As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

The respiratory pathogen testing kits market may rise from USD 4,304.6 Million in 2025 to USD 7,352.9 Million by 2035, with a CAGR of 5.5% over the forecast period. The global respiratory pathogen ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

Twenty five countries have reported outbreaks, including newly affected Sierra Leone where infections are surging.

On Friday, Kentucky announced two pertussis deaths in infants over the past 6 months, and neither the infants nor their ...